Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03182920 · ClinicalTrials.gov registry record · Phase 1
A Study of Lasmiditan in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT03182920 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 35 participants.
The verdict
NCT03182920, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to look at the amount of study drug that gets into the blood stream and how long it takes the body to get rid of it by comparing the results of healthy elderly participants to those of healthy young participants. The tolerability of the study drug will be evaluated. Information about any side effects that may occur will also be collected. This study will last up to approximately 19 days, not including screening. This study requires either one (Group 2) or two (Group 1) stays at the clinic each of at least four days/three nights. Participants will return for a follow-up seven days after last dose of study drug. Screening is required within 28 days prior to Day 1. This study is for research purposes only and is not intended to treat any medical condition.
Interventions
- DRUG Placebo
- DRUG Lasmiditan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2017-06-16 |
| Est. Completion | 2017-08-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03182920
The ClinicalTrials.gov registry entry for NCT03182920 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03182920 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03182920 about?
NCT03182920 is a clinical study titled "A Study of Lasmiditan in Healthy Participants". The purpose of this study is to look at the amount of study drug that gets into the blood stream and how long it takes the body to get rid of it by comparing the results of healthy elderly participants to those of healthy young participants. The tolerability of the study drug will be evaluated. Info...
What is the current status of trial NCT03182920?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2017-06-16. Estimated completion is 2017-08-14.
What interventions are being tested in trial NCT03182920?
The interventions under investigation include: Placebo (DRUG), Lasmiditan (DRUG).
Who is sponsoring clinical trial NCT03182920?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.